See more : Koatsu Gas Kogyo Co., Ltd. (4097.T) Income Statement Analysis – Financial Results
Complete financial analysis of Eisai Co., Ltd. (ESAIY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Eisai Co., Ltd., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Shenzhen Zqgame Co., Ltd (300052.SZ) Income Statement Analysis – Financial Results
- Plum Acquisition Corp. I (PLMIU) Income Statement Analysis – Financial Results
- Tiger Royalties and investments Plc (TIR.L) Income Statement Analysis – Financial Results
- G1 Secure Solutions Ltd (GOSS.TA) Income Statement Analysis – Financial Results
- Blue Star Helium Limited (BSNLF) Income Statement Analysis – Financial Results
Eisai Co., Ltd. (ESAIY)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.eisai.co.jp
About Eisai Co., Ltd.
Eisai Co., Ltd. engages in the research and development, manufacture, sale, and import and export of pharmaceuticals in Japan. It offers Dayvigo, for the treatment of insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; Methycobal for the treatment of peripheral neuropathy; and Halaven, an anticancer agent for the treatment of breast cancer. The company also provides Jyseleca, a janus kinase inhibitor; Elental, a branched-chain amino acid preparation; Goofice and Movicol for chronic constipation; Fycompa, an antiepileptic agent; Pariet, a proton-pump inhibitor; Aricept, for Alzheimer's disease/Dementia with Lewy bodies; and Chocola BB plus for the preparation vitamin B2. It has strategic collaboration with Bristol Myers Squibb for the co-development and co-commercialization of farletuzumab ecteribulin antibody drug conjugate. Eisai Co., Ltd. was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 741.75B | 744.40B | 756.23B | 645.94B | 695.62B | 642.83B | 600.05B | 539.10B | 547.92B | 548.47B | 600.35B | 573.68B | 647.93B | 768.93B | 803.14B | 781.71B | 734.42B | 674.18B | 601.26B | 533.14B | 500.13B | 466.61B | 431.75B | 361.71B | 302.47B |
| Cost of Revenue | 155.33B | 177.84B | 174.83B | 161.31B | 175.69B | 184.49B | 201.25B | 195.91B | 194.46B | 193.60B | 188.16B | 174.11B | 173.35B | 167.78B | 160.73B | 152.41B | 118.94B | 109.37B | 104.51B | 98.61B | 97.18B | 102.47B | 101.57B | 98.60B | 91.68B |
| Gross Profit | 586.42B | 566.57B | 581.40B | 484.63B | 519.93B | 458.34B | 398.80B | 343.19B | 353.46B | 354.87B | 412.20B | 399.57B | 474.57B | 601.15B | 642.41B | 629.29B | 615.48B | 564.81B | 496.75B | 434.53B | 402.95B | 364.15B | 330.18B | 263.11B | 210.79B |
| Gross Profit Ratio | 79.06% | 76.11% | 76.88% | 75.03% | 74.74% | 71.30% | 66.46% | 63.66% | 64.51% | 64.70% | 68.66% | 69.65% | 73.24% | 78.18% | 79.99% | 80.50% | 83.81% | 83.78% | 82.62% | 81.50% | 80.57% | 78.04% | 76.47% | 72.74% | 69.69% |
| Research & Development | 169.02B | 173.00B | 171.74B | 150.30B | 140.12B | 144.84B | 139.58B | 112.48B | 122.31B | 131.91B | 130.54B | 120.38B | 0.00 | 0.00 | 0.00 | 0.00 | 225.43B | 108.30B | 93.25B | 78.33B | 69.02B | 59.70B | 55.04B | 49.61B | 46.70B |
| General & Administrative | 374.42B | 358.29B | 366.43B | 281.40B | 256.30B | 228.21B | 183.86B | 179.68B | 192.82B | 194.55B | 152.32B | 139.85B | 0.00 | 0.00 | 0.00 | 0.00 | 372.30B | 351.25B | 307.80B | 269.39B | 250.87B | 228.44B | 202.46B | 154.66B | 127.05B |
| Selling & Marketing | -10.34B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 58.22B | 68.88B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 364.08B | 358.29B | 366.43B | 281.40B | 256.30B | 228.21B | 183.86B | 179.68B | 192.82B | 194.55B | 210.54B | 208.73B | 0.00 | 0.00 | 0.00 | 0.00 | 372.30B | 351.25B | 307.80B | 269.39B | 250.87B | 228.44B | 202.46B | 154.66B | 127.05B |
| Other Expenses | 0.00 | 0.00 | -10.52B | 1.17B | -1.99B | -866.00M | -1.85B | -8.03B | -13.60B | 80.00M | -109.00M | -138.00M | 924.00M | 924.00M | 417.00M | -9.00M | 616.00M | 873.00M | 459.00M | 555.00M | -43.00M | 1.00M | 864.00M | -130.00M | -96.00M |
| Operating Expenses | 532.79B | 526.53B | 527.65B | 432.87B | 394.43B | 372.19B | 321.59B | 284.13B | 301.53B | 326.53B | 341.09B | 329.10B | 378.82B | 488.03B | 556.00B | 537.48B | 597.73B | 459.55B | 401.04B | 347.72B | 319.88B | 288.15B | 257.49B | 204.14B | 173.66B |
| Cost & Expenses | 688.12B | 704.36B | 702.48B | 594.18B | 570.12B | 556.68B | 522.84B | 480.03B | 495.99B | 520.13B | 529.25B | 503.21B | 552.17B | 655.81B | 716.73B | 689.90B | 716.67B | 568.91B | 505.55B | 446.33B | 417.06B | 390.62B | 359.06B | 302.75B | 265.34B |
| Interest Income | 10.80B | 7.24B | 2.40B | 2.15B | 4.02B | 4.86B | 2.56B | 1.85B | 2.02B | 2.43B | 963.00M | 1.12B | 815.00M | 997.00M | 1.25B | 3.17B | 5.33B | 5.12B | 3.35B | 1.70B | 1.34B | 1.47B | 2.78B | 3.19B | 0.00 |
| Interest Expense | 2.39B | 2.27B | 1.69B | 1.36B | 1.46B | 1.56B | 2.97B | 3.24B | 3.49B | 4.89B | 5.55B | 6.69B | 6.89B | 7.42B | 7.66B | 7.63B | 762.00M | 65.00M | 79.00M | 52.00M | 28.00M | 56.00M | 296.00M | 687.00M | 1.13B |
| Depreciation & Amortization | 39.40B | 39.98B | 38.40B | 36.30B | 33.70B | 26.84B | 26.18B | 26.48B | 34.06B | 38.94B | 48.52B | 51.09B | 48.69B | 51.26B | 57.37B | 58.63B | 34.40B | 26.80B | 24.99B | 22.45B | 18.49B | 15.33B | 15.33B | 15.00B | 15.14B |
| EBITDA | 103.11B | 87.26B | 94.55B | 90.05B | 162.94B | 117.75B | 105.81B | 86.93B | 87.99B | 69.56B | 93.36B | 129.21B | 150.23B | 161.25B | 139.31B | 136.75B | 52.81B | 137.20B | 121.15B | 110.06B | 101.90B | 87.85B | 91.74B | 58.53B | 41.81B |
| EBITDA Ratio | 13.90% | 11.72% | 12.50% | 13.97% | 23.46% | 18.33% | 17.66% | 16.21% | 16.06% | 12.71% | 19.86% | 21.84% | 22.48% | 21.31% | 18.02% | 19.04% | 7.35% | 20.37% | 20.80% | 20.93% | 20.37% | 18.05% | 21.25% | 15.70% | 13.82% |
| Operating Income | 53.41B | 40.04B | 53.75B | 51.77B | 125.50B | 86.15B | 77.21B | 59.06B | 51.94B | 28.34B | 71.11B | 70.46B | 95.75B | 113.12B | 86.41B | 91.81B | 17.75B | 105.26B | 95.70B | 86.81B | 83.06B | 75.86B | 72.69B | 58.97B | 37.13B |
| Operating Income Ratio | 7.20% | 5.38% | 7.11% | 8.01% | 18.04% | 13.40% | 12.87% | 10.96% | 9.48% | 5.17% | 11.84% | 12.28% | 14.78% | 14.71% | 10.76% | 11.74% | 2.42% | 15.61% | 15.92% | 16.28% | 16.61% | 16.26% | 16.84% | 16.30% | 12.28% |
| Total Other Income/Expenses | 8.42B | 4.97B | 708.00M | -668.00M | 2.56B | 3.30B | -409.00M | -1.40B | -1.46B | -2.46B | -4.10B | 966.00M | -1.10B | -10.55B | -12.13B | -21.32B | -96.00M | 5.07B | 378.00M | 845.00M | -539.00M | -6.04B | -9.93B | -16.13B | -11.60B |
| Income Before Tax | 61.82B | 45.01B | 54.46B | 52.55B | 128.06B | 89.45B | 76.80B | 57.67B | 50.47B | 25.88B | 58.21B | 71.43B | 94.65B | 102.57B | 74.28B | 70.48B | 17.65B | 110.33B | 96.08B | 87.65B | 82.52B | 69.83B | 62.75B | 42.84B | 25.54B |
| Income Before Tax Ratio | 8.33% | 6.05% | 7.20% | 8.14% | 18.41% | 13.92% | 12.80% | 10.70% | 9.21% | 4.72% | 9.70% | 12.45% | 14.61% | 13.34% | 9.25% | 9.02% | 2.40% | 16.37% | 15.98% | 16.44% | 16.50% | 14.96% | 14.53% | 11.84% | 8.44% |
| Income Tax Expense | 18.04B | -11.82B | 8.74B | 10.07B | 5.60B | 22.97B | 22.38B | 15.42B | -4.57B | -17.58B | 25.03B | 22.88B | 35.71B | 34.79B | 33.41B | 22.13B | 37.19B | 39.20B | 32.23B | 31.80B | 32.93B | -28.61B | 26.10B | 19.63B | -14.20B |
| Net Income | 42.41B | 55.43B | 47.95B | 41.94B | 121.77B | 63.39B | 51.85B | 39.36B | 54.93B | 43.25B | 32.96B | 48.28B | 58.51B | 67.39B | 40.34B | 47.68B | -17.01B | 70.61B | 63.41B | 55.51B | 50.15B | 41.03B | 36.80B | 23.32B | 11.28B |
| Net Income Ratio | 5.72% | 7.45% | 6.34% | 6.49% | 17.50% | 9.86% | 8.64% | 7.30% | 10.03% | 7.89% | 5.49% | 8.42% | 9.03% | 8.76% | 5.02% | 6.10% | -2.32% | 10.47% | 10.55% | 10.41% | 10.03% | 8.79% | 8.52% | 6.45% | 3.73% |
| EPS | 147.86 | 193.31 | 167.27 | 146.95 | 425.01 | 221.02 | 724.71 | 550.52 | 768.92 | 606.28 | 536.52 | 677.52 | 821.32 | 946.08 | 566.32 | 669.40 | -59.32 | 991.40 | 887.24 | 776.88 | 697.04 | 553.36 | 500.64 | 311.51 | 152.13 |
| EPS Diluted | 147.86 | 193.30 | 167.25 | 146.90 | 424.80 | 221.02 | 723.89 | 549.64 | 767.04 | 605.48 | 536.04 | 677.24 | 821.24 | 946.04 | 566.24 | 669.20 | -59.32 | 991.40 | 887.24 | 776.88 | 697.04 | 553.36 | 500.64 | 311.51 | 152.13 |
| Weighted Avg Shares Out | 286.80M | 286.76M | 286.69M | 286.62M | 286.51M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M |
| Weighted Avg Shares Out (Dil) | 286.80M | 286.76M | 286.73M | 286.71M | 286.65M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M | 286.80M |
The 3 Best Biotech Stocks to Buy Now: September 2023
Biotech stocks have underperformed in the U.S. stock market by a wide margin this year. The sector's most popular index, the iShares Biotechnology ETF (NASDAQ: IBB ), is down 5% since Jan. 27.
Merck and Eisai cull late-stage study for head and neck cancer therapy
Merck & Co Inc (NYSE:MRK) and research partner Eisai said they are halting a late-stage trial that used a combination of drugs to treat a type of head and neck cancer after it didn't result in an overall survival benefit...
Merck and Eisai say late-stage trial of treatment for head and neck cancer did not meet goals
Merck & Co. Inc. MRK, -1.66% and Eisai Co. Ltd. 4523, -1.23% ESAIY, -1.95% said Friday a late-stage trial of a treatment for head and neck cancer failed to meet its main goals and the companies have decided to shut...
Merck, Eisai discontinue late-stage study for cancer therapy
Merck & Co and partner Eisai said on Friday they will shut down a late-stage study testing an experimental combination therapy for a type of head and neck cancer after an interim analysis showed it failed to prolong lives of...
3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes
The pharmaceutical sector generates a huge $1.2 trillion of revenue globally, and the U.S. is by far the most lucrative country for drug makers in the world. Therefore, the profits of successful American pharmaceutical firms can be truly staggering.
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023
Further Phase 3 analysis shows benefits of lecanemab on both amyloid-beta and tau, two underlying pathological hallmarks of Alzheimer's disease New data on subcutaneous formulation shows promising PK /PD data modeling on efficacy and safety, representing a potential new option...
EISAI TO PRESENT THE LATEST ALZHEIMER'S DISEASE PIPELINE AND RESEARCH, INCLUDING LECANEMAB AND ANTI-MTBR TAU ANTIBODY E2814, AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2023
TOKYO , July 11, 2023 /PRNewswire/ -- Eisai Co. Ltd (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that the company will present the latest findings on its Alzheimer's disease (AD) pipeline and research, including Eisai's anti-amyloid beta (Aβ) protofibril*...
Eisai exec who helped steer Alzheimer's drug approval to retire in July
The Eisai executive who helped garner full U.S. approval for the Japanese drugmaker's Alzheimer's disease treatment Leqembi will retire at the end of this month, the company said on Tuesday.
Leqembi approval offers renewed hope for novel Alzheimer's disease treatments
US officials have granted full approval to Leqembi, the first medication to demonstrate modest effectiveness in slowing cognitive decline associated with Alzheimer's disease. Developed by Japanese drug-maker Eisai and comarketed with Biogen Inc (NASDAQ:BIIB), the American pharmaceutical giant, the FDA's...
FDA Approves New Alzheimer's Drug But Creators Biogen And Eisai Stock Slides
Eisai saw its stock fall 4.67% on the news and Biogen was down 2.07%.
Source: https://incomestatements.info
Category: Stock Reports